375345-99-6

Upstream product

• 64-04-0 phenethylamine 
• 33893-36-6 N-(methylsulfonyl)(2-phenylethyl)amine 
• 353235-94-6 N-(t-butoxycarbonyl)-N-(2-(4-iodophenyl)ethyl)-N-(methylsulfonyl)amine 
• 353235-93-5 N-(2-(4-iodophenyl)ethyl)-N-(methylsulfonyl)amine 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 353235-95-7 N-(t-butoxycarbonyl)-N-(methylsulfonyl)-N-(2-(4-(4,4,5,5-tetramethyl(1,3,2-dioxaborolan-2-yl))phenyl)ethyl)amine 

Downstream Products

• 375345-95-2 {(2R)-2-[4-(4-{2-[(methylsulfonyl)amino]ethyl}phenyl)phenyl]-propyl}[(methylethyl)sulfonyl]amine 
• 516491-32-0 N,N'-([1,1'-biphenyl]-4,4'-diyldi-2,1-ethanediyl)-bis-methanesulfonamide 
• 375346-00-2 [4-[2-[(methylsulfonyl)amino]ethyl]phenyl]boronic acid 

Relevant academic research and scientific papers

HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF

The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula (I) as defined in the specification. The invention is also directed to compositions containing and uses of

Suppression of a palladium-mediated homocoupling in a Suzuki cross-coupling reaction. Development of an impurity control strategy supporting synthesis of LY451395

Described herein is the development of a control strategy resulting in exclusion of a persistent impurity (6) formed by a palladium (II)-mediated homocoupling of boronic acid (3) during a Suzuki cross-coupling reaction. Nearly complete suppression of the undesired homocoupling reaction was achieved through two process modifications. Thus, addition of a mild reducing agent, potassium formate, and use of a facile nitrogen subsurface sparge prior to introduction of the catalyst resulted in nearly complete exclusion of homocoupling dimer 6. These modifications apparently minimized the concentration of free Pd(II) in the reaction mixture without causing significant reduction of the oxidative addition product. In addition, use of palladium black as a heterogeneous coupling catalyst rendered the palladium control strategy trivial. Thus, the catalyst was separated from the product solution through use a clarifying filtration, resulting in near quantitative separation of palladium from LY 451395 (5). These conditions were successfully executed in three campaigns using 3-, 5-, 12-, and 22-L glassware.

Cyclopentyl sulfonamide derivatives

The present invention provides compounds of formula (I): useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.

Sulfonamide derivatives

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.

Process for preparing biphenyl compounds

The present invention relates to a process for the preparation of a biphenyl compound comprising combining a phenyl boronic acid derivative with an halobenzene derivative in the presence of a suitable additive in a suitable organic solvent with a suitable catalyst and a suitable base.

Combination therapy for treatment of depression

The present invention provides a method for treating depression, comprising administering to a patient an effective amount of a first component which is a suitable antidepressant, in combination with an effective amount of a second component which is a suitable AMPA receptor potentiator.